Results 261 to 267 of about 122,918,365 (267)

Association between METS-VF and sarcopenia among middle-aged and older adults in China: The first longitudinal evidence from CHARLS

Experimental Gerontology
Hongyuan Cui, Tianhan Sun
exaly  

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

International Journal of Molecular Sciences, 2018
Federica Papaccio, Fortunato Ciardiello, Carminia Maria Della Corte   +2 more
exaly  

A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025

Lung Cancer: Targets and Therapy
Sai-Hong Ignatius Ou
exaly  

‘The house was on fire.' Top Chinese virologist on how China and U.S. have met the pandemic

Science, 2020
exaly  

How powerful can a language test be? The met in China

Journal of Multilingual and Multicultural Development, 1990
exaly  

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial

Lancet, The
Zhigang Han, Yongxin Ren, Qisen Guo
exaly  

Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model

Frontiers in Pharmacology
exaly